

A DECLARATION OF JOINT WORKING BETWEEN

Bristol Heart Institute, University Hospitals Bristol and Weston NHS Foundation Trust (UHBW),
Bristol, BS2 8HW

AND

AstraZeneca UK, 2 Pancras Square, 8th Floor, London, N1C 4AG

relating to

Implementation of a heart failure clinic for cardiac devices patients

Summary of the project:

University Hospitals Bristol and Weston NHS Foundation Trust serves a core population of more than 500,000 people. As part of that service the Bristol Heart Institute has a long-standing cardiac devices clinic which sees around 2500 patients per year.

In 2021 the data for 164 of these patients were audited and 54 (36%) had an LVEF \leq 40%, of whom 33 (61%) were not currently being managed under a BHI heart failure clinic. Current capacity constraints mean that these patients could not be accommodated within the existing services.

Data on current medical heart failure therapy was available in 24 (73%) of whom none of the patients (0%) were optimised on all four pillars. The overall breakdown is as follows: 26% ARNI, 54% MRA, 4% SGLT2 inhibitor. It is therefore estimated that up to 480 patients in the BHI device clinic have an LVEF \leq 40%, are not currently under a BHI heart failure service, and are not currently prescribed all four medical heart failure drug classes. They would benefit from a new pathway to initiate and up-titrate their medical heart failure therapy.

The aims and objectives of the project are:

To enable access for a subset of HF patients, with severe disease to specialist opinion and current optimal medical therapy. This will reduce local inequalities, allowing those diagnosed with HF in the past to access current optimal medical therapies.

For the estimated 150 patients, it is envisaged that the optimisation of their HF medications should result in an improvement in their symptom burden and quality of life. This includes:

- Improvement to individual medication regimes - number of patients on optimal 4 pillar GDMT
- Improved patient symptoms as assessed by NYHA

Timeframes:

The project will run from December 2022 to December 2023. Both parties have contributed resources to the initiative.